Neuropep Therapeutics
Neuropep Therapeutics is developing a two-track platform to treat Alzheimer's and Parkinson's by addressing neuropeptide depletion rather than amyloid accumulation. The company's lead candidate is a novel oral monotherapy protecting endogenous neuropeptides from degradation, derived from an FDA-approved drug and associated with a 52.5% reduction in Alzheimer's incidence in real-world data. A second track involves second-generation non-aggregating peptide analogues designed to replace lost neuropeptides and restore synaptic function.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Alzheimer's and Parkinson's diseases have been predominantly researched and treated under the amyloid hypothesis, yet anti-amyloid drugs that achieved significant plaque clearance have failed to show meaningful cognitive improvement in clinical trials. This decades-long, heavily funded approach has yielded no disease-modifying cures, leaving patients with progressive synaptic failure and cognitive decline, while the underlying mechanism of neuropeptide depletion remains largely unaddressed. With a projected 153 million Alzheimer's patients globally by 2050 and $1.3 trillion in annual US dementia costs, the need for a fundamentally different therapeutic approach is urgent.
Solution
Neuropep Therapeutics is pioneering a paradigm shift in treating neurodegeneration by targeting neuropeptide depletion rather than amyloid accumulation. The company's two-track platform addresses the disease through complementary mechanisms: first, a novel oral monotherapy that protects endogenous neuropeptides from degradation, built on an FDA-approved drug with an established safety profile and demonstrating a 52.5% reduction in Alzheimer's incidence in real-world patient data; second, second-generation non-aggregating peptide analogues with enhanced brain penetration and optimized stability to replace lost neuropeptides and restore synaptic function. This dual approach aims to move from prevention to potential reversal of disease, restoring what the brain needs at the molecular level. The platform is positioned on the depletion branch of neurodegeneration, a mechanism the human data implicates but which remains almost entirely unexplored by competitors.
Target Audience
Primary stakeholders include Alzheimer's and Parkinson's patients, neurologists, and clinical researchers seeking disease-modifying therapies, as well as investors and healthcare systems looking for alternatives to the exhausted amyloid hypothesis.
Features
- Oral monotherapy formulation protecting endogenous neuropeptides from degradation, derived from an FDA-approved therapeutic with a de-risked development pathway
- Second-generation non-aggregating peptide analogues with novel structural modifications, enhanced brain penetration, and optimized stability
- Real-world evidence showing 52.5% reduction in Alzheimer's incidence across independent cohorts for the oral monotherapy candidate
- Proprietary formulation representing new intellectual property distinct from the existing approved drug
- Two-track platform addressing neurodegeneration at multiple stages, from prevention to potential reversal
- Non-dilutive grant capital already secured for the clinical trial